UK markets closed

Oxford BioMedica plc (OXB.L)

LSE - LSE Delayed price. Currency in GBp
Add to watchlist
1,320.00+2.00 (+0.15%)
At close: 04:36PM GMT

Oxford BioMedica plc

Windrush Court
Transport Way
Oxford OX4 6LT
United Kingdom
44 1865 783 000

Full-time employees744

Key executives

NameTitlePayExercisedYear born
Mr. John DawsonCEO & Exec. Director964kN/A1960
Mr. Stuart PaynterCFO, Company Sec. & Director549kN/A1973
Mr. Nick PageChief Operations OfficerN/AN/AN/A
Dr. James Miskin Ph.D.Chief Technical OfficerN/AN/AN/A
Dr. Kyriacos Mitrophanous Ph.D.Chief Scientific OfficerN/AN/AN/A
Mr. Matthew TreagusChief Information OfficerN/AN/AN/A
Ms. Catherine Isted A.C.M.A.Head of Corp. Devel. & IRN/AN/AN/A
Ms. Natalie Louise WalterGen. CounselN/AN/AN/A
Ms. Sarah MacleodHead of CommunicationsN/AN/AN/A
Ms. Helen Stephenson-EllisChief People OfficerN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.


Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various diseases in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes. The company's products under development stage include OXB-302 that targets haematological tumours with a CAR-T 5T4; OXB-203, which is in pre-clinical stage for the treatment of wet age-related macular degeneration; OXB-204, a lentiviral-based therapy for the ocular disease Leber's congenital amaurosis variant 10; OXB-103 (ALS) for central nervous system; and OXB-401 for liver indication. Its partnered products in development stage comprise AXO-Lenti-PD that is in a Phase I/II trial preparation for the treatment of Parkinson's disease; SAR 422459, which is in a Phase II trial for the treatment of Stargardt disease; and SAR 421869 that is in Phase I/II trial for the treatment of Usher syndrome 1B. Oxford Biomedica plc has partnerships with Novartis, Bristol Myers Squibb, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations, Santen Pharmaceutical Co Ltd, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Papyrus Therapeutics, Inc. to assess the impact and therapeutic benefit of PYTX-002, a gene replacement therapy to confer cellular pharmacy properties on a CAR-T cell therapy. It has a discovery collaboration with PhoreMost Limited to develop CAR-T cell therapies. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.

Corporate governance

Oxford BioMedica plc’s ISS governance QualityScore as of 26 September 2021 is 8. The pillar scores are Audit: 8; Board: 7; Shareholder rights: 1; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.